Enanta Pharmaceuticals (ENTA) Short-term Investments (2012 - 2026)

Enanta Pharmaceuticals has reported Short-term Investments for 15 years, with the latest figure at $128.8 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 3.24% year-over-year to $128.8 million; the trailing twelve-month figure through Mar 2026 stood at $128.8 million (down 3.24% YoY), and the FY2025 full-year result was $156.6 million, down 25.78% from the prior year.
• Short-term Investments for Q1 2026 stood at $128.8 million, down from $148.4 million in the prior quarter.
• The five-year high for Short-term Investments was $297.2 million in Q4 2023, with the low at $128.8 million in Q1 2026.
• Historically, Short-term Investments has averaged $191.7 million across 5 years, with a median of $183.3 million in 2022.
• The largest YoY upside for Short-term Investments was 72.94% in 2024 against a maximum downside of 55.47% in 2024.
• Enanta Pharmaceuticals' Short-term Investments stood at $172.2 million in 2022, then soared by 72.55% to $297.2 million in 2023, then sank by 55.47% to $132.3 million in 2024, then rose by 12.14% to $148.4 million in 2025, then retreated by 13.18% to $128.8 million in 2026.
• The last three Short-term Investments figures came in at $128.8 million (Q1 2026), $148.4 million (Q4 2025), and $156.6 million (Q3 2025), per Business Quant data.